Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
type 1 diabetes mellitus 1 endocrinologydiseases
Insulin 12 endocrinologydiseasesdrugs
diabetes insipidus 1 endocrinologydiseases
diabetes mellitus 2 endocrinologydiseases
hyperglycemia 8 endocrinologydiseases
hypoglycemia 10 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Insulin 82 Title: The PatientQuality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy ImplicationsPaulo H. R. F.
Insulin 124 PatientQuality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin : A Systematic Review and Policy ImplicationsPaulo H. R. F. AlmeidaThales B. C. SilvaFrancisco de Assis
Insulin 467 (epub): 1/2018Publication date (pmc-release): 1/2018Publication date (ppub): /2018AbstractIntroduction Insulin analog glargine (GLA) has been available as one of the therapeutic options for patients with type 1
Insulin 11384 (PubMed)((((((((((((((((((Diabetic Ketoacidosis[MeSH Terms]) OR Diabetes Mellitus, Type 1[MeSH Terms]) OR Diabetes Mellitus, Insulin *Dependent[Text Word]) OR Insulin-Dependent Diabetes Mellitus[Text Word]) OR Juvenile-Onset Diabetes
Insulin 11417 Terms]) OR Diabetes Mellitus, Type 1[MeSH Terms]) OR Diabetes Mellitus, Insulin*Dependent[Text Word]) OR Insulin -Dependent Diabetes Mellitus[Text Word]) OR Juvenile-Onset Diabetes Mellitus[Text Word]) OR Type 1 Diabetes
Insulin 11663 Sudden-Onset Diabetes Mellitus[Text Word]) OR Diabetes Mellitus, Type I[Text Word]) OR IDDM[Text Word]) OR Insulin *Dependent Diabetes Mellitus 1[Text Word]) OR Juvenile*Onset Diabetes[Text Word]) OR Brittle Diabetes
Insulin 11974 Fields] AND Text Word) OR Autoimmune Diabetes[Text Word]) NOT diabetes insipidus[MeSH Terms])) AND ((((((( Insulin , Isophane[MeSH Terms]) OR Isophane Insulin[Text Word]) OR NPH Insulin[Text Word]) OR NPH[Text Word])
Insulin 12017 Diabetes[Text Word]) NOT diabetes insipidus[MeSH Terms])) AND (((((((Insulin, Isophane[MeSH Terms]) OR Isophane Insulin [Text Word]) OR NPH Insulin[Text Word]) OR NPH[Text Word]) OR Protamine Hagedorn Insulin[Text Word])
Insulin 12044 insipidus[MeSH Terms])) AND (((((((Insulin, Isophane[MeSH Terms]) OR Isophane Insulin[Text Word]) OR NPH Insulin [Text Word]) OR NPH[Text Word]) OR Protamine Hagedorn Insulin[Text Word]) OR Neutral Protamine Hagedorn
Insulin 12105 OR Isophane Insulin[Text Word]) OR NPH Insulin[Text Word]) OR NPH[Text Word]) OR Protamine Hagedorn Insulin [Text Word]) OR Neutral Protamine Hagedorn Insulin[Text Word]))) OR (((((((LY2963016 insulin glargine
Insulin 12155 Insulin[Text Word]) OR NPH[Text Word]) OR Protamine Hagedorn Insulin[Text Word]) OR Neutral Protamine Hagedorn Insulin [Text Word]))) OR (((((((LY2963016 insulin glargine [Supplementary Concept]OR glargine[Text Word]) OR
Insulin 12345 glargine[Text Word]) OR lantus[Text Word]) OR insulin glargine[Text Word]) OR HOE*901[Text Word])) OR “ Insulin , Long-Acting”[Mesh])) AND (((((((((((((((((((((((((((((((((((((“quality of life”[MeSH Terms])
Select Disease Character Offset Disease Term Instance
diabetes insipidus 11930 Mellitus[Text Word]) OR Diabetes, Autoimmune[All Fields] AND Text Word) OR Autoimmune Diabetes[Text Word]) NOT diabetes insipidus [MeSH Terms])) AND (((((((Insulin, Isophane[MeSH Terms]) OR Isophane Insulin[Text Word]) OR NPH Insulin[Text
diabetes mellitus 575 analog glargine (GLA) has been available as one of the therapeutic options for patients with type 1 diabetes mellitus to enhance glycemic control. Studies have shown that a decrease in the frequency of hypoglycemic episodes
diabetes mellitus 29301 hypoglycemiaNRNRNRPerception of hyperglycemiaNRNRNRADDQoL Audit of Diabetes Dependent Quality of Life Questionnaire, DM diabetes mellitus , DQOL Diabetes Quality of Life Measure, DTSQ Diabetes Quality of Life Measure (DTSQs evaluates treatment
hyperglycemia 5114 coronary artery disease), as well as acute complications, which includes episodes of hypoglycemia and hyperglycemia associated with T1DM [[2], [13]].However, in two systematic reviews (SRs), no benefits for GLA compared
hyperglycemia 19385 satisfaction with current treatment, perceived frequency of hypoglycemia, and perceived frequency of hyperglycemia . DTSQc uses the same domains as DTSQs, but it has different response options and asks respondents to
hyperglycemia 27036 al. [[35]] DTSQsSatisfaction with treatmentNRNRNR8.48.4NSHypoglycemia perceptionNRNRPerception of hyperglycemia NRNRGallen and Carter [[36]] W-BQ28Negative perception of well-beingNRNRNS8.47.760.006*EnergyNRNR0.001*Total
hyperglycemia 27431 treatment23.7 (SD ± 0.85)28.1 (SD ± 0.87)0.001*Perception of hypoglycemiaNRNRNRPerception of hyperglycemia NRNRNRManini et al. [[37]] WEDSymptoms15.3 (SD ± 2.7)16.1 (SD ± 2.4)0.040*8.47.60.0001*Discomfort13.1
hyperglycemia 28256 [[40]] DTSQsSatisfaction with treatment27.5329.110.001*NRNRNRPerception of hypoglycemia2.252.20NSPerception of hyperglycemia 2.702.250.038* W-BQ22General well-being50.9751.56NSDepression3.343.31NSAnxiety3.673.67NSEnergy8.318.82NSPositive
hyperglycemia 28696 treatment23.7 (SD ± 0.7)32.3 (SD ± 0.7)0.001*7.58.00.001*Perception of hypoglycemiaNRNRNRPerception of hyperglycemia 4.0 (SD ± 0.2)2.7 (SD ± 0.2)0.001 DTSQcSatisfaction with treatment13.5 (SD ± 1.7)− 0.4 (SD ± 1.8)0.001*Perception
hyperglycemia 28874 treatment13.5 (SD ± 1.7)− 0.4 (SD ± 1.8)0.001*Perception of hypoglycemiaNRNRNRPerception of hyperglycemia NRNRNR ADDQolSocial life and work lifeNRNRNRAverage weighted impact (AWI)− 1.7 (SD ± 0.1)− 1.4(SD ± 0.1)0.003*QoL
hyperglycemia 29213 [[42]] DTSQsSatisfaction with treatment28.4029.60.006*7.87.90.719Perception of hypoglycemiaNRNRNRPerception of hyperglycemia NRNRNRADDQoL Audit of Diabetes Dependent Quality of Life Questionnaire, DM diabetes mellitus, DQOL Diabetes
hypoglycemia 4562 mimics the insulin secretion of individuals without DM. This has resulted in a decrease in episodes of hypoglycemia as well as better glycemic control, mainly glycated hemoglobin (HbA1c), compared with NPH insulin in
hypoglycemia 5097 carotid disease, and coronary artery disease), as well as acute complications, which includes episodes of hypoglycemia and hyperglycemia associated with T1DM [[2], [13]].However, in two systematic reviews (SRs), no benefits
hypoglycemia 7138 versus NPH insulin would promote better QoL, as GLA insulin could lead to a decrease in the episodes of hypoglycemia and would also cause less discomfort to patients. There have been several SRs to assess differences
hypoglycemia 19344 follow-up. DTSQ presents three domains: satisfaction with current treatment, perceived frequency of hypoglycemia , and perceived frequency of hyperglycemia. DTSQc uses the same domains as DTSQs, but it has different
hypoglycemia 27399 well-beingNRNR0.006* DTSQsSatisfaction with treatment23.7 (SD ± 0.85)28.1 (SD ± 0.87)0.001*Perception of hypoglycemia NRNRNRPerception of hyperglycemiaNRNRNRManini et al. [[37]] WEDSymptoms15.3 (SD ± 2.7)16.1 (SD ± 2.4)0.040*8.47.60.0001*Discomfort13.1
hypoglycemia 28220 (27–34)0.05Witthaus et al. [[40]] DTSQsSatisfaction with treatment27.5329.110.001*NRNRNRPerception of hypoglycemia 2.252.20NSPerception of hyperglycemia2.702.250.038* W-BQ22General well-being50.9751.56NSDepression3.343.31NSAnxiety3.673.67NSEnergy8.318.82NSPositive
hypoglycemia 28664 [[41]] DTSQsSatisfaction with treatment23.7 (SD ± 0.7)32.3 (SD ± 0.7)0.001*7.58.00.001*Perception of hypoglycemia NRNRNRPerception of hyperglycemia4.0 (SD ± 0.2)2.7 (SD ± 0.2)0.001 DTSQcSatisfaction with treatment13.5
hypoglycemia 28842 (SD ± 0.2)0.001 DTSQcSatisfaction with treatment13.5 (SD ± 1.7)− 0.4 (SD ± 1.8)0.001*Perception of hypoglycemia NRNRNRPerception of hyperglycemiaNRNRNR ADDQolSocial life and work lifeNRNRNRAverage weighted impact
hypoglycemia 29181 (SD ± 0.1)0.014Polonsky et al. [[42]] DTSQsSatisfaction with treatment28.4029.60.006*7.87.90.719Perception of hypoglycemia NRNRNRPerception of hyperglycemiaNRNRNRADDQoL Audit of Diabetes Dependent Quality of Life Questionnaire,
hypoglycemia 31612 favor of GLA insulin in two out of the four domains: satisfaction with treatment and perception of hypoglycemia .Ashwell et al. [[41]] found statistically significant differences in favor of GLA insulin in two out
type 1 diabetes mellitus 568 /2018AbstractIntroductionInsulin analog glargine (GLA) has been available as one of the therapeutic options for patients with type 1 diabetes mellitus to enhance glycemic control. Studies have shown that a decrease in the frequency of hypoglycemic episodes

You must be authorized to submit a review.